Schrodinger (SDGR) & Its Rivals Head to Head Survey

Schrodinger (NASDAQ:SDGR) is one of 93 publicly-traded companies in the “Healthcare Technology” industry, but how does it compare to its rivals? We will compare Schrodinger to similar businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, risk and dividends.

Insider and Institutional Ownership

79.0% of Schrodinger shares are owned by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are owned by institutional investors. 10.1% of Schrodinger shares are owned by company insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Schrodinger and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrodinger	-22.02%	-18.12%	-9.07%
Schrodinger Competitors	-751.01%	-29.51%	-15.37%

Earnings & Valuation

This table compares Schrodinger and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Schrodinger	$255.87 million	-$103.26 million	-36.68
Schrodinger Competitors	$342.20 million	-$24.15 million	12.64

Schrodinger’s rivals have higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Schrodinger has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Schrodinger’s rivals have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Schrodinger and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1	3	4	0	2.38
Schrodinger Competitors	455	1536	2751	89	2.51

Schrodinger presently has a consensus target price of $26.67, indicating a potential downside of 7.98%. As a group, “Healthcare Technology” companies have a potential upside of 44.28%. Given Schrodinger’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Schrodinger has less favorable growth aspects than its rivals.

Summary

Schrodinger rivals beat Schrodinger on 8 of the 13 factors compared.

About Schrodinger

Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.